STOCK TITAN
  1. Home
  2. Sec-filings
  3. GNTA
  4. [6-K] Genenta Science S.p.A. Current Report (Foreign Issuer)

Genenta (GNTA) faces court suspension of broad corporate purpose change

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
6-K

Rhea-AI Filing Summary

Genenta Science S.p.A. describes an interim order from the Court of Milan concerning two past shareholder resolutions. The court declined to suspend the May 2, 2024 resolution introducing a multiple voting rights mechanism, so that mechanism and related voting rights remain in effect.

The court temporarily suspended the October 29, 2025 resolution that amended Genenta’s corporate purpose, citing concerns that the provision is overly broad and linked to future “Golden Power” legislative changes. Existing transactions, including those involving ATC and Sophia High Tech, are not affected.

Genenta has appealed the suspension before a panel of the Court of Milan, with a hearing scheduled for July 9, 2026. Depending on the outcome, the corporate purpose amendment may remain effective or be revised and resubmitted to shareholders.

Positive

  • None.

Negative

  • None.

Insights

Court upholds Genenta’s voting structure but pauses its broad corporate purpose amendment.

The Court of Milan refused to suspend Genenta’s multiple voting rights mechanism from May 2, 2024, so the enhanced voting structure for longer-term holders continues to apply. The order explicitly notes no unlawful conduct by the company, directors, or shareholders regarding this mechanism.

Conversely, the court temporarily suspended the October 29, 2025 corporate purpose amendment, finding the reference to all sectors under Italy’s evolving “Golden Power” regime potentially too broad and dynamic. Existing transactions, including those with ATC and Sophia High Tech, remain valid under the order’s terms.

An appeal was filed on June 22, 2026, with a hearing set for July 9, 2026. That decision will shape whether Genenta retains the broader corporate purpose or needs a more specific formulation to submit to shareholders, which may influence how flexibly it can pursue future strategic projects in Italy.

Multiple voting rights resolution date May 2, 2024 Date the multiple voting rights mechanism was adopted
Corporate purpose amendment date October 29, 2025 Date the now-suspended corporate purpose amendment was approved
Appeal filing date June 22, 2026 Date Genenta filed precautionary appeal in Milan
Appeal hearing date July 9, 2026 Scheduled Court of Milan hearing on Genenta’s appeal
Golden Power reference All sectors covered Corporate purpose referenced all sectors under Italy’s Golden Power regime
multiple voting rights mechanism financial
"the resolution adopted on May 2, 2024 introducing a multiple voting rights mechanism"
corporate purpose financial
"the resolution adopted on October 29, 2025 amending the Company’s corporate purpose"
Golden Power regime regulatory
"which references all sectors covered by the Italian “Golden Power” regime"
precautionary proceeding regulatory
"an interim order in a precautionary proceeding initiated by certain minority shareholders"
forward-looking statements regulatory
"This Report on Form 6-K contains forward-looking statements within the meaning of applicable securities laws"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

FAQ

Did the court suspend Genenta Science’s multiple voting rights mechanism?
No, the Court of Milan denied suspension of the May 2, 2024 multiple voting rights resolution. It found the minority shareholders’ objections insufficient and noted the mechanism aims to promote long-term shareholding stability and support medium- to long-term corporate strategies.

What happened to Genenta Science’s October 29, 2025 corporate purpose amendment?
The court granted a precautionary request to suspend the October 29, 2025 corporate purpose amendment. It viewed the provision, which referenced all Italian “Golden Power” sectors as amended over time, as possibly overly broad, heterogeneous, and dynamically linked to future legislative changes.

Are Genenta Science’s past transactions affected by the court’s suspension order?
The order suspends the effectiveness of the October 29, 2025 corporate purpose amendment going forward. It does not invalidate, unwind, or suspend transactions previously approved or entered into while that resolution was in effect, including those involving ATC and Sophia High Tech.

How is Genenta Science (GNTA) responding to the Court of Milan’s order?
Genenta has filed a precautionary appeal challenging the suspension of the corporate purpose amendment. The appeal will be heard on July 9, 2026. If unsuccessful, management may convene a shareholders’ meeting to consider a narrower, more specific corporate purpose formulation.

Does the court order allege unlawful conduct by Genenta or its directors?
No, the order explicitly states it does not contain findings of unlawful conduct by Genenta, its directors, or its shareholders regarding adoption or implementation of the multiple voting rights mechanism. The concerns focus instead on the breadth and structure of the corporate purpose amendment.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 6-K: How Foreign Companies Report to the SEC →

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of June 2026

 

Commission File Number: 001-41115

 

GENENTA SCIENCE S.P.A.

(Translation of registrant’s name into English)

 

Via dell’Annunciata 31

20121 Milan, Italy

(Address of Principal Executive Offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☒ Form 40-F ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

 

This report on Form 6-K is incorporated by reference into the registrant’s registration statement on Form S-8 (File No. 333-278392).

 

 

 

 

 

 

Other Events

 

Genenta Science S.p.A. (“Genenta” or the “Company”) announces that the Court of Milan has issued an interim order in a precautionary proceeding initiated by certain minority shareholders seeking suspension of two shareholder resolutions: (i) the resolution adopted on May 2, 2024 introducing a multiple voting rights mechanism, and (ii) the resolution adopted on October 29, 2025 amending the Company’s corporate purpose.

 

The Court denied the request to suspend the May 2, 2024 resolution concerning the multiple voting rights mechanism. In its order, the Court determined that the objections raised by the claimants with respect to the multiple voting rights mechanism did not justify the suspension requested. The Court noted, among other things, that the mechanism was introduced with the objective of promoting long-term shareholding stability and supporting medium- to long-term corporate strategies.

 

As a result, the multiple voting rights mechanism remains in effect, and the Court did not suspend voting rights exercised pursuant to that mechanism. The order does not contain any findings of unlawful conduct by the Company, its directors, or its shareholders in connection with the adoption or implementation of the multiple voting rights mechanism.

 

The Court granted the precautionary request with respect to the October 29, 2025 resolution amending the Company’s corporate purpose and ordered suspension of that resolution pending further proceedings. The Court’s concerns relate to the breadth and formulation of the corporate purpose provision, which references all sectors covered by the Italian “Golden Power” regime as amended from time to time. The Court determined, on an interim basis, that the provision may be overly broad, heterogeneous, and dynamically linked to future legislative changes.

 

The operative provision of the order suspends the efficacy of the October 29, 2025 resolution pending further proceedings but does not invalidate, unwind, or suspend transactions previously approved or entered into by the Company while that resolution was in effect, including transactions involving ATC and Sophia High Tech.

 

The Company has challenged the order by filing a precautionary appeal before the competent panel of the Court of Milan on Monday, June 22, 2026. Through the appeal, the Company seeks reversal of the portion of the order suspending the October 29, 2025 resolution. The hearing before the Court of Milan to discuss the appeal has been scheduled for July 9, 2026.

 

If the appeal is successful, the amendment to the corporate purpose will remain effective. If the appeal is unsuccessful, the Company may convene a shareholders’ meeting to consider approval of a revised formulation of the corporate purpose that more specifically identifies the sectors in which the Company intends to operate.

 

Forward-Looking Statements

 

This Report on Form 6-K contains forward-looking statements within the meaning of applicable securities laws, including statements regarding the Company’s anticipated appeal, the outcome of legal proceedings, the continued effectiveness of the Company’s corporate purpose amendment, the potential convening of a shareholders’ meeting, and the Company’s strategic plans and future operations. These forward-looking statements are based on current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. The Company undertakes no obligation to update any forward-looking statements except as required by law.

  

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  GENENTA SCIENCE S.P.A.
     
  By: /s/ Pierluigi Paracchi
  Name:  Pierluigi Paracchi
  Title: Chief Executive Officer

 

Dated: June 26, 2026

 

 

Source: View Original Filing on SEC EDGAR